SANTORO, ARMANDO
 Distribuzione geografica
Continente #
AS - Asia 132
NA - Nord America 84
EU - Europa 24
SA - Sud America 4
AF - Africa 2
Totale 246
Nazione #
SG - Singapore 112
US - Stati Uniti d'America 79
CN - Cina 14
IE - Irlanda 5
SE - Svezia 5
DE - Germania 4
VN - Vietnam 4
BR - Brasile 3
CA - Canada 2
FI - Finlandia 2
FR - Francia 2
GB - Regno Unito 2
HK - Hong Kong 2
MX - Messico 2
PL - Polonia 2
ZA - Sudafrica 2
BB - Barbados 1
EC - Ecuador 1
ES - Italia 1
NL - Olanda 1
Totale 246
Città #
Singapore 48
Ashburn 28
Beijing 5
Chandler 5
Dublin 5
Buffalo 4
Dallas 3
Denver 3
Los Angeles 3
Munich 3
New York 3
Santa Clara 3
Atlanta 2
Boardman 2
Guangzhou 2
Hong Kong 2
Johannesburg 2
Montreal 2
Nanchang 2
Querétaro 2
Warsaw 2
Ambato 1
Ann Arbor 1
Augusta 1
Boston 1
Bridgetown 1
Changsha 1
Charleston 1
Chicago 1
Contagem 1
Da Nang 1
Frankfurt am Main 1
Helsinki 1
Ho Chi Minh City 1
Ituiutaba 1
La Rochelle 1
Leawood 1
London 1
Long An 1
Lấp Vò 1
Marseille 1
Nanjing 1
Norwalk 1
Orem 1
Poplar 1
Princeton 1
Seattle 1
Shenyang 1
Taquara 1
Turku 1
Totale 160
Nome #
Activity of Pemetrexed on brain metastases from Non-Small Cell Lung Cancer 96
A Comparative Study of Methyl-BEAMing and Droplet Digital PCR for MGMT Gene Promoter Hypermethylation Detection 11
Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma 8
Advanced colorectal liver metastases and surgery after preoperative chemotherapy : is response-based selection enough? 8
A Phase II Randomized Dose Escalation Trial of Sorafenib in Patients with Advanced Hepatocellular Carcinoma 8
Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications 8
Aggressive and Multidisciplinary Local Approach to Iterative Recurrences of Colorectal Liver Metastases 8
Can stereotactic body radiation therapy be a viable and efficient therapeutic option for unresectable locally advanced pancreatic adenocarcinoma? Results of a phase 2 study 8
Fatal Infusion Reaction to Cetuximab: The Need for Predictive Risk Factors and Safer Patient Selection 7
Role of stereotactic body radiation therapy in the management of oligometastatic pancreatic cancer single institution experience 7
FOLFIRI and Cetuximab Every Second Week for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer According to Phosphatase and Tensin Homolog Expression: A Phase II Study 7
A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study 7
Emergence of KRAS-mutation in liver metastases after an anti-EGFR treatment in patient with colorectal cancer: are we aware of the therapeutic impact of intratumor heterogeneity? 7
COVID-19 and liver cancer clinical trials: not everything is lost 6
Phase I, pharmacokinetics, pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors 6
Determinants of Treatment Benefit and Post-Treatment Survival for Patients with Hepatocellular Carcinoma Enrolled in Second-Line Trials after the Failure of Sorafenib Treatment 6
Hepatotoxicity in Patients with Hepatocellular Carcinoma on Treatment with Immune Checkpoint Inhibitors 6
Effect of Comorbidities in Stage II/III Colorectal Cancer Patients Treated With Surgery and Neoadjuvant/Adjuvant Chemotherapy: A Single-Center, Observational Study 6
Budget impact of bimonthly use of cetuximab in patients diagnosed with metastatic colorectal cancer 6
Biomarkers in Hepatocellular Carcinoma-Letter 6
Cabozantinib for the treatment of hepatocellular carcinoma 6
Pembrolizumab in MMR-proficient metastatic colorectal cancer pharmacologically primed to trigger dynamic hypermutation status: The ARETHUSA trial 6
Clinical results of stereotactic body radiotherapy (SBRT) in the treatment of isolated local recurrence of pancreatic cancer after R0 surgery: A retrospective study 5
Implementing Pre-Therapeutic UGT1A1 Genotyping in Clinical Practice: A Real-Life Study 4
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomized, placebo-controlled phase 2 study 3
Tivantinib for hepatocellular carcinoma 3
Regorafenib in hepatocellular carcinoma: latest evidence and clinical implications 2
Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib 2
Standardisation of EGFR FISH in colorectal cancer: results of an international interlaboratory reproducibility ring study 2
Reply to Y. Pointreau et al 2
Progression of Colorectal Liver Metastases from the End of Chemotherapy to Resection: A New Contraindication to Surgery? 2
Tivantinib for Second-line Treatment of Advanced MET-High Hepatocellular Carcinoma: A Phase 3, Randomized, Placebo-Controlled Study (METIV-HCC) 2
Sorafenib in hepatitis C-virus negative patients with hepatocellular carcinoma: don’t throw the baby out with the bathwater 2
The role of hepatic metastases and pulmonary tumor burden in predicting survival after complete pulmonary resection for colorectal cancer 2
Prognostic value of the neutrophil-to-lymphocyte ratio in hepatocellular carcinoma: an exploratory analysis from the second-line ARQ 197-215 study 2
Molecular determinants of outcome in sorafenib-treated patients with hepatocellular carcinoma 2
Tivantinib: a new promising mesenchymal-epithelial transition factor inhibitor in the treatment of hepatocellular carcinoma 2
Regorafenib in patients with refractory metastatic pancreatic cancer: a Phase II study (RESOUND) 2
Stereotactic Ablative Radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer: a safe and effective approach 2
Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma 1
Pharmacological inactivation of DNA repair to improve response to immunotherapy: The Arethusa trial in metastatic colorectal cancer 1
Regorafenib for the treatment of unresectable hepatocellular carcinoma 1
Totale 288
Categoria #
all - tutte 1.598
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.598


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20213 0 0 0 0 0 0 0 0 1 0 2 0
2021/20222 0 0 0 0 0 0 0 1 0 0 0 1
2022/202318 3 3 1 1 1 2 0 1 6 0 0 0
2023/20247 0 2 0 0 1 2 0 1 0 0 0 1
2024/202523 0 1 1 3 2 3 0 0 4 1 3 5
2025/2026225 5 4 5 3 104 104 0 0 0 0 0 0
Totale 288